Logo Tafalgie Therapeutics

Tafalgie Therapeutics,
Research contributing to health & well-being

Innovative polypeptides for the prevention and treatment of pain.

Spin off from CNRS and AMU is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous and secreted protein modulating the pain signal.

picto-scientific

tafalgie & our ambition ?

Become the reference player in the field of pain by designing and proposing new active pharmaceutical ingredients for non-opioid analgecics in a context marked by the opioid crisis through the development of a first in class polyptides derived from TAF and its peptide derivatives.

picto-pipeline

tafalgie & our goal ?

We aim to develop and bring to patients more effective, well-tolerated, non-addictive, long-term treatments for the relief of acute pain – mild, moderate and severe – as well as for the prevention of chronic pain. Our medium-term strategic objective is to enter into partnership agreements with major pharmaceutical companies or specialized international distributors who will be able to bring the products resulting from the TAFA4 technology to the market.

Project chronology
& history

Tafalgie Therapeutics capitalizes on more than ten years of promising French scientific work.

APPROCH & context

Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein able to modulate the transmission of pain information to the brain. 

Pipeline

Tafalgie Therapeutics has developed and identified other new drug candidates.

Global urgency to develop new antalgics

0
Millions

surgeries are performed each year.

0 %
patients
date undergo surgery are affected.
0
Millions
0 %
patients

OUR expert TEAM

Tafalgie Therapeutics gathers around its management team and founding partners, a Scientific Committee and a Supervisory Board

aziz moqrich

CSO

Specialist of the peripheral nervous system
Publication in International Journal

Eric schettini

President 

Investor Biotech Entrepreneur
Successful IPOs
25 years experience

laurent labatut

Chairman of board

Chemical Industry
Strategic positions in Marketing
Scale up

stephane gaillard

General Manager

Pain research
Mice Models Characterization
Production

olivier blin

Chairman of the COMEX

Professor of clinical pharmacology (AMU)

Past positions : Regulatory Industrial

Site Inserm

Aziz Moqrich explains to Thierry Lhermitte (FranceInter) how pain is modulate in our body.

Listen our podcast on franceinter

Tafalgie Therapeutics

Spin off from CNRS and AMU is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous and secreted protein modulating the pain signal.